S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners

Agile Therapeutics Stock Price, News & Analysis (NASDAQ:AGRX)

$2.11
+0.03 (+1.44%)
(As of 11/28/2023 ET)
Compare
Today's Range
$2.00
$2.11
50-Day Range
$1.73
$2.60
52-Week Range
$1.65
$16.00
Volume
12,500 shs
Average Volume
54,344 shs
Market Capitalization
$5.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Agile Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
302.9% Upside
$8.50 Price Target
Short Interest
Healthy
0.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
0.43mentions of Agile Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars


AGRX stock logo

About Agile Therapeutics Stock (NASDAQ:AGRX)

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.

AGRX Stock Price History

AGRX Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Agile Therapeutics reports Q3 results
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
See More Headlines
Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGRX
Fax
N/A
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$12.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+302.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-25,410,000.00
Pretax Margin
-69.73%

Debt

Sales & Book Value

Annual Sales
$10.88 million
Book Value
($6.83) per share

Miscellaneous

Free Float
2,499,000
Market Cap
$5.30 million
Optionable
Not Optionable
Beta
1.81
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Alfred F. AltomariMr. Alfred F. Altomari (Age 64)
    Chairman, President & CEO
    Comp: $644.4k
  • Mr. Geoffrey P. Gilmore (Age 57)
    Senior VP & Chief Administrative Officer
    Comp: $478.92k
  • Dr. Paul Korner M.B.A. (Age 57)
    M.D., Senior VP & Chief Medical Officer
    Comp: $480.4k
  • Mr. Scott M. Coiante (Age 56)
    CFO, Senior VP & Treasurer
    Comp: $520.45k
  • Matthew Riley
    Head of Investor Relations & Corporate Communications
  • Mr. Robert G. Conway M.E. (Age 65)
    Senior VP and Chief Corporate Planning & Supply Chain Officer
    Comp: $444.11k
  • Ms. Amy Welsh (Age 52)
    Senior VP & Chief Commercial Officer
  • Joseph D'Urso
    Controller














AGRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Agile Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGRX shares.
View AGRX analyst ratings
or view top-rated stocks.

What is Agile Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued 12 month price objectives for Agile Therapeutics' shares. Their AGRX share price targets range from $5.00 to $12.00. On average, they predict the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 302.9% from the stock's current price.
View analysts price targets for AGRX
or view top-rated stocks among Wall Street analysts.

How have AGRX shares performed in 2023?

Agile Therapeutics' stock was trading at $0.2270 at the start of the year. Since then, AGRX stock has increased by 829.5% and is now trading at $2.1099.
View the best growth stocks for 2023 here
.

Are investors shorting Agile Therapeutics?

Agile Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 18,000 shares, an increase of 12.5% from the October 31st total of 16,000 shares. Based on an average daily trading volume, of 40,600 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.8% of the shares of the company are short sold.
View Agile Therapeutics' Short Interest
.

When is Agile Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our AGRX earnings forecast
.

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics, Inc. (NASDAQ:AGRX) issued its earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($7.20) EPS for the quarter, topping analysts' consensus estimates of ($7.60) by $0.40. The specialty pharmaceutical company earned $1.29 million during the quarter, compared to analyst estimates of $1.49 million. During the same quarter in the previous year, the business posted ($7.20) EPS.

When did Agile Therapeutics' stock split?

Agile Therapeutics's stock reverse split before market open on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What guidance has Agile Therapeutics issued on next quarter's earnings?

Agile Therapeutics updated its FY 2023 earnings guidance on Thursday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $25.00M-, compared to the consensus revenue estimate of $21.66 million.

What other stocks do shareholders of Agile Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).

Who are Agile Therapeutics' major shareholders?

Agile Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (5.08%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alfred Altomari, Dennis Reilly, Jason Butch and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Agile Therapeutics?

Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AGRX) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -